Zydus Lifesciences Limited Earnings Summary — Q1 FY2027
Zydus Lifesciences Reports Q1 FY27 Revenue Growth of 22% Amid Strategic Acquisitions and Exceptional Litigation Settlements
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue has increased for 4 consecutive quarters.
- Revenue of ₹8,017 Cr is 22.0% higher year-on-year.
- Revenue has compounded at 17.9% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit of ₹940 Cr is 35.9% below the same quarter last year.
- Profit growth is trailing revenue growth this quarter.
- Net profit has compounded at -9.7% annualised across the period.
- Operating margin stands at 24.1% in Q1 FY2027.
- Operating margin compressed by 770 bps year-on-year.
- Over the last two years operating margin has contracted by 950 bps.
- PBT margin is 16.3%.
- Expenses grew 35.7% against revenue growth of 22.0%.
- Operating profit of ₹1,929 Cr is 7.6% lower year-on-year.
- Operating leverage has been under pressure recently.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 50/100 (Moderate) on the latest 10 quarters.
- Business momentum has softened and warrants monitoring.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 8,017 | 7,587 | 6,865 | 6,123 | 6,574 | 6,528 | 5,269 | 5,237 | 6,208 | 5,534 |
| Expenses | Accelerating | 6,088 | 5,033 | 5,048 | 4,107 | 4,485 | 4,402 | 3,882 | 3,776 | 4,124 | 3,903 |
| Operating Profit | Improving | 1,929 | 2,554 | 1,816 | 2,016 | 2,089 | 2,126 | 1,388 | 1,461 | 2,084 | 1,631 |
| Operating Margin | Stable | 24.1% | 33.7% | 26.5% | 32.9% | 31.8% | 32.6% | 26.3% | 27.9% | 33.6% | 29.5% |
| Other Income | Volatile | 88 | -263 | 27 | 75 | 155 | -139 | 57 | 69 | 63 | 160 |
| Interest | Improving | 156 | 123 | 130 | 101 | 85 | 77 | 32 | 25 | 32 | 35 |
| Depreciation | Strong Uptrend | 555 | 508 | 360 | 302 | 238 | 238 | 229 | 234 | 215 | 205 |
| Profit Before Tax | Stable | 1,307 | 1,660 | 1,353 | 1,687 | 1,921 | 1,672 | 1,184 | 1,271 | 1,900 | 1,550 |
| Tax | Volatile | 354 | 318 | 388 | 454 | 434 | 423 | 180 | 373 | 436 | 321 |
| Net Profit | Stable | 940 | 1,273 | 1,042 | 1,259 | 1,467 | 1,171 | 1,024 | 911 | 1,420 | 1,182 |
| Net Margin | Softening | 11.7% | 16.8% | 15.2% | 20.6% | 22.3% | 17.9% | 19.4% | 17.4% | 22.9% | 21.4% |
Key Takeaways
- Revenue from operations grew 22% YoY to ₹80,170 million, driven by strong growth in the Consumer products and Medical technologies segments.
- The quarter was impacted by significant exceptional items including a ₹1,091 million provision for severance at Assertio and a ₹559 million antitrust settlement.
- Partially offsetting exceptional costs was a ₹1,468 million litigation settlement receipt from Teva Pharmaceutical Industries related to an Asset Purchase Agreement.
- Zydus completed the acquisition of Assertio Holdings, Inc. on June 16, 2026, for a total consideration of approximately USD 166.4 million.
- The company successfully executed a share buyback of 8,730,158 equity shares at ₹1,260 per share, totaling ₹11,063 million, reducing equity capital by 0.87%.
- Operating margins faced pressure during the quarter, dropping to 16.5% compared to 29.2% in the same quarter last year, partly due to increased employee and finance costs.
Management Guidance
Management is focused on integrating the newly acquired Assertio and Agenus assets while navigating USFDA regulatory observations at legacy facilities.
Sentiment Shift
Deteriorating
While top-line growth is robust due to M&A, profitability and margins have sharply declined compared to both the prior year and sequential quarter due to integration costs and exceptional litigation provisions.
Outlook
The company expects to finalize Purchase Price Allocations (PPA) for several recent acquisitions (Amplitude, Comfort Click, Assertio) within the next measurement periods while continuing to focus on complex generics and chronic therapies.
From the Annual Report (Key Quotes)
“ZPUI remains committed to conducting its business in full compliance with all applicable laws.”
“The transaction of the cash tender offer... has been completed on June 16, 2026. Subsequently, Zara was merged with and into Assertio.”
“The tax expenses for the quarter ended June 30, 2026 is not comparable with other reported periods due to re-measurement of deferred tax assets.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Zydus Lifesciences Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.